Le Lézard
Classified in: Health, Science and technology
Subjects: HEALTH, MISCELLANEOUS

Philips recognized as top innovator for 10th consecutive year


February 16, 2023

Company once again on Clarivate Top 100 Global Innovator list for consistent high performance and scale in innovativeness

Amsterdam, the Netherlands ? Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has once again been recognized as a Clarivate Top 100 Global Innovatortm in Clarivate Analytics' 2023 list, which measures excellence focused on consistency and scale in innovativeness [1], thanks to its constant high performance on these metrics. Philips has now been included in this reputable list for 10 consecutive years.

"Our innovations empower people to take care of their health and well-being and help doctors and nurses to provide better, more sustainable and more convenient care," said Roy Jakobs, CEO of Royal Philips. "It's a great honor to be recognized as a Top 100 Global Innovator for the 10th consecutive year, along with so many esteemed companies. Building on our more than 130 years of delivering meaningful innovation, we will continue to innovate with great passion, with our goal to improve 2.5 billion lives a year by 2030."

Philips is one of the world's leading innovators in health technology, investing more than EUR 1.7 billion annually in research and development to deliver patient- and people-centric innovation. With its global presence, strong informatics platforms, ambulatory monitoring and imaging data, and personal health offerings, as well as strong capabilities to support care across settings, Philips is well positioned to help improve people's health and healthcare outcomes, and make care more convenient and sustainable, both in the hospital and at home.

In the consumer domain, Philips develops innovative solutions that support healthier lifestyles, prevent disease, and help people to live well with chronic illness, also in the home and community settings. In clinics and hospitals, Philips cooperates closely with healthcare providers to innovate and transform the way care is delivered. This includes flagship innovations such as:

The full Top 100 Global Innovators 2023 report and full list can be found here.

[1]    The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power. To move from the individual idea strength to identify the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years. For full information on the methodology used to identify the 2023 list, see here.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: [email protected]

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments



These press releases may also interest you

at 23:20
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

at 23:07
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...

at 21:03
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

at 21:00
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...

at 20:54
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2...



News published on and distributed by: